Advertisement

DNP - Der Neurologe & Psychiater

, Volume 20, Issue 6, pp 84–92 | Cite as

Patientenorientierte Therapieziele

Recovery in der Behandlung der Schizophrenie: Vision oder Realität?

  • Kristina AdorjanEmail author
  • Peter Falkai
Zertifizierte Fortbildung
  • 17 Downloads

Zusammenfassung

In den vergangenen 20 Jahren ist die „Recovery“ als Therapieziel in den Fokus der Behandlung von Menschen mit Schizophrenie gerückt. Um sie zu erreichen, sind möglichst präzise Diagnoseverfahren, die Einbeziehung biologischer Faktoren und eine angemessene Behandlung erforderlich.

Literatur

  1. 1.
    Kahn RS et al. Schizophrenia. Nat Rev Dis Primers. 2015 Nov 12;1:15067.CrossRefGoogle Scholar
  2. 2.
    Charlson FJ et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018 Oct 17;44(6):1195–1203.CrossRefGoogle Scholar
  3. 3.
    Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75 Suppl 1:8–14.CrossRefGoogle Scholar
  4. 4.
    Knuf A et al. (Hg.). Selbstbefähigung fördern. Empowerment und psychiatrische Arbeit. Bonn Psychiatrie Verlag. 5., überarb. A. 2006.Google Scholar
  5. 5.
    Häfner H et al. In Hirsch et al. Schizophrenia, Blackwell 2003, p.101-141.Google Scholar
  6. 6.
    Pick A. Ueber primäre chronische Demenz (so. Dementia praecox) im jugendlichen Alter. Prager medicinische Wochenschrift 1891; 16:312–315.Google Scholar
  7. 7.
    Kraepelin E. Dementia Praecox and Paraphrenia. Barclay RM, Robertson GM (trans). New York, RE Krieger, 1919.Google Scholar
  8. 8.
    Bleuler E. Dementia Praecox, or The Group of Schizophrenias. New York, International Universities Press, 1950.Google Scholar
  9. 9.
    Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5®. Deutsche Ausgabe Hg. Falkai P u. Wittchen HU. 2017.Google Scholar
  10. 10.
    S3-Leitlinie Schizophrenie. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN) (Hrsg.). https://www.dgppn.de/leitlinien-publikationen/leitlinien.html.
  11. 11.
    Hirayasu Y et al. Lower left temporal lobe MRI volumes in patients with first-episode schizophrenic compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry 1998; 155:1384–1391.CrossRefGoogle Scholar
  12. 12.
    Egerton A et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry 2013; 74:106–112.CrossRefGoogle Scholar
  13. 13.
    de la Fuente-Sandoval C et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011; 36:1781–1791.CrossRefGoogle Scholar
  14. 14.
    Manoach DS et al. Reduced Sleep spindles in schizophrenia: a treatable endophenotype that links risk genes to impaired cognition? Biol Psychiatry 2016; 80:599–608.Google Scholar
  15. 15.
    Bodatsch M et al. Prediction of psychosis by mismatch negativity. Biol Psychiatry 2011; 69:959–966.CrossRefGoogle Scholar
  16. 16.
    Perez VB et al. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients forecasting psychosis risk with mismatch negativity. Biol Psychiatry 2014; 75:459–469CrossRefGoogle Scholar
  17. 17.
    Fisher DJ et al. The neurophysiology of schizophrenia: Current update and future directions. Int J Psychophysiol. 2019 Nov;145:1–4.CrossRefGoogle Scholar
  18. 18.
    Burmeister M et al. Psychiatric genetics: progress amid controversy. Nat Rev Genet. 2008;9(7):527–540.CrossRefGoogle Scholar
  19. 19.
    Jia JM et al. The schizophrenia susceptibility gene dysbindin regulates dendritic spine dynamics. J Neurosci. 2014 Oct 8;34(41):13725–36.CrossRefGoogle Scholar
  20. 20.
    Prata DP et al. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet. 2009 Jun;19(3):113–6.CrossRefGoogle Scholar
  21. 21.
    Ripke S et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427.CrossRefGoogle Scholar
  22. 22.
    Saho L et al. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol. Psych. 64(2) 2008: 89–97.CrossRefGoogle Scholar
  23. 23.
    Power RA et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Molecular Psychiatry. 2014;19:1201–1204.CrossRefGoogle Scholar
  24. 24.
    Goes FS. Genetics ofbipolardisorder: recent update and future directions. Psychiatr Clin North Am 39:139–155.Google Scholar
  25. 25.
    Dreher J. (Hg.) Psychopharmakotherapie griffbereit. Medikamente, psychoaktive Genussmittel und Drogen, 4. Auflage, Thieme Verlag, Stuttgart, NY 2019: 62-109.Google Scholar
  26. 26.
    Lally J et. al. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015 Jun;114(1):169–79.CrossRefGoogle Scholar
  27. 27.
    Taylor M et al. Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Ther Adv Psychopharmacol. 2019; 9: 2045125319870033.Google Scholar
  28. 28.
    Naber D et al. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009 Aug;23(8):649–59.PubMedGoogle Scholar
  29. 29.
    Richardson MA et al. Evidence for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology. 2005;52(4):190–201.CrossRefGoogle Scholar
  30. 30.
    Law AJ et al. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet. 2007;16: 129–141.CrossRefGoogle Scholar
  31. 31.
    Hashimoto R et al. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry, 2004;9: 299–307.CrossRefGoogle Scholar
  32. 32.
    Wehr MC et al. Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice. EMBO Mol Med. 2017 Oct;9(10):1448–1462.CrossRefGoogle Scholar
  33. 33.
    Neustädter M et al. Successful treatment in the day clinic of the Clinic for Psychiatry and Psychotherapy of LMU Munich. Experienced changes from the patients’ perspective. MMW Fortschr Med. 2018 Nov;160(Suppl 5):6–10.CrossRefGoogle Scholar
  34. 34.
    Deister A (Hg.). Milieutherapie. In: Mo.ller H-J, Laux G, Kapf- hammer H-P, editors. Psychiatrie und Psychotherapie, 2. Auflage. Berlin, Heidelberg: Springer; 2003. p. 772–91.Google Scholar
  35. 35.
    Donner-Banzhoff N. Partizipative Entscheidungsfindung. In: Pfaff H, Neugebauer E, Glaeske G, Schrappe M, (Hg.). Lehrbuch der Versorgungsforschung: Systematik — Methodik — Anwendung. Stuttgart Schattauer, 2011 p. 64–7.Google Scholar
  36. 36.
    Sartorius N et al. WPA guidance on how to combat stigmatization of psychiatry and psychiatrists. World Psychiatry. 2010;9:131–44CrossRefGoogle Scholar
  37. 37.
    Adorjan K et al. Ability to work and mental disorders. MMW Fortschr Med. 2014 Sep 11;156(15):49–51.CrossRefGoogle Scholar
  38. 38.
    Bond GR et al. An update on supported employment for people with severe mental illness. Psychiatr Serv 1997. 48:335–46.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Psychiatrie und Psychotherapie, Institut für Psychiatrische Phänomik und GenomikKlinikum der Universität München (LMU)MünchenDeutschland
  2. 2.Klinik für Psychiatrie und PsychotherapieKlinikum der Universität München (LMU)MünchenDeutschland

Personalised recommendations